Similarly, Mithramycin A and NVP-BGT226 increased the drug efficacy of CDX-011 in vitro in most TFE3-fusion RCC cell lines tested (Fig. 5A,B; Supplementary Figure S9A). Here, TFE3 is linked to renal cell carcinoma.